Showing results (161-170 of 445) with videos related to
Sort By:
Pageof 45
Data in Brief|July 14, 2021
Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baselineBergur V Stefánsson, Hiddo J L Heerspink, David C Wheeler, et al.International Journal of Cancer|September 27, 2014
Relationship between ambient ultraviolet radiation and non-Hodgkin lymphoma subtypes: a U.S. population-based study of racial and ethnic groupsElizabeth K Cahoon, Ruth M Pfeiffer, David C Wheeler, et al.Clinical Journal of the American Society of Nephrology : CJASN|November 22, 2022
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without DiabetesPriya Vart, Muthiah Vaduganathan, Niels Jongs, et al.Psychosomatic Medicine|June 17, 2020
Stress Reactivity as a Contributor to Racial and Socioeconomic Disparities: Rationale and Baseline Results From the Richmond Stress and Sugar StudyBriana Mezuk, Evanise Lexima, Viktoryia A Kalesnikava, et al.Journal of Diabetes and Its Complications|September 19, 2020
Correction of anemia by dapagliflozin in patients with type 2 diabetesBergur V Stefánsson, Hiddo J L Heerspink, David C Wheeler, et al.BMC Medicine|October 9, 2022
New strategies to improve clinical outcomes for diabetic kidney diseaseThomas Forst, Chantal Mathieu, Francesco Giorgino, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 30, 2020
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 DiabetesDavid C Wheeler, June James, Dipesh Patel, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|September 1, 2023
Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and HypoglycemiaThomas Ebert, Nosheen Sattar, Marni Greig, et al.Pharmacoepidemiology and Drug Safety|May 27, 2015
Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all-cause mortalityIain A Gillespie, Jürgen Floege, Ioanna Gioni, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 10, 2024
The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trialRon T Gansevoort, David C Wheeler, Francisco Martínez Debén, et al.Pageof 45